On February 11 local time, SpringWorks Therapeutics announced that the U.S. FDA had approved its MEK inhibitor Gomekli.（mirdametinib）Launched for the treatment of patients withType 1 Neurofibromatosis(NF1) And Symptomatic Plexiform Neurofibromas(PN) And cannot be completely removedPatients aged 2 years and above, including both adults and children. The press release noted that this isThe first and only drug approved for the treatment of NF1-PN in adults and children.The product isSpringWorks Therapeutics was introduced from Pfizer.Screenshot source: Corporate official website
Type 1 Neurofibromatosis (NF1) Is a rare genetic disorder caused by mutations in the NF1 gene, which encodes neurofibromin, a key inhibitor of the MAPK pathway. Patients with NF1 have a lifelong risk of developing plexiform neurofibromas.(PN) The risk is approximately 30%-50%. These tumors grow in an infiltrative pattern along the peripheral nerve sheath, potentially causing severe disfigurement, pain, and dysfunction; in very rare cases, NF1-PN can be fatal.Due to the infiltrative growth pattern of tumors along nerves, surgical resection of these tumors is challenging and may lead to permanent nerve damage and deformities. Up to approximately 85% of plexiform neurofibromas are considered unresectable.Gomekl is an orally administered small-molecule MEK inhibitor that has previously been granted Priority Review, Fast Track designation, and Orphan Drug designation by the FDA for the treatment of NF1-PN.This approval is based on the results of the Phase Ⅱb ReNeu trial, which enrolled 114 patients with NF1-PN aged ≥2 years.(58 adults and 56 pediatric patients)The data showed that Gomekli achieved an objective response rate. (ORR) The primary endpoint, ORR in adult patients was 41%（24/ 58）, the ORR for pediatric patients was 52%.（29/56）。The tumor volume of patients receiving treatment significantly reduced and the effect was durable; the median of the optimal percentage change in target PN volume was -41% in adult patients and -42% in pediatric patients.In adult and pediatric patients, 88% and 90% of patients, respectively, had a duration of response lasting at least 12 months; additionally, 50% and 48% of patients, respectively, had a duration of response lasting at least 24 months. According to assessments using multiple patient-reported outcome tools, both groups experienced significant and sustained improvements in pain and quality of life from baseline.In terms of safety, Gomekli demonstrated controllable safety and tolerability. The most common adverse events reported in adult patients (>25%) The most common adverse events in pediatric patients are rash, diarrhea, nausea, musculoskeletal pain, vomiting, and fatigue. (>25%) Rash, diarrhea, musculoskeletal pain, abdominal pain, vomiting, headache, paronychia, left ventricular dysfunction, and nausea.This is SpringWorks Therapeutics, Inc.Second FDA Approval in Less Than 18 Months。SpringWorks Therapeutics, Inc. was founded in 2017 and is dedicated to improving the lives of patients with severe rare diseases and cancer. From its inception, the company hasPfizer has introduced four clinical-stage drug candidates.Among them, two have been approved for marketing: one is the MEK inhibitor Gomekl, which has just been approved this time; the other is the oral γ-secretase inhibitor Ogsiveo.（nirogacestat）, which was approved by the FDA in November 2023 for the treatment of adult patients with progressive desmoid tumors requiring systemic therapy, is the first FDA-approved drug for the treatment of desmoid tumors.In addition, according to the Insight database, the company has multiple products in clinical research and preclinical stages.Screenshot source: Insight database
Notably, recent reports from foreign media indicate that Merck, the German pharmaceutical giant（Merck KGaA）In-depth negotiations are underway for the acquisition of SpringWorks Therapeutics. Following this news, shares of SpringWorks surged 34% on Monday.Cover Source:Regulatory AuthorityDisclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.PR Article Coordination: WeChat insightxbSubmissionWeChat: insightxb; Email: insight@dxy.cn
Diversified functions, traceable data……Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock！
